Regeneron, gene therapy and hearing loss

Regeneron's gene therapy study shows improved hearing in children with congenital deafness
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old born with hearing loss caused by gene mutations.
Regeneron gene therapy improves children’s hearing
In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss, 10 out of 11 have shown improvements after being treated with a gene therapy. “What is really remarkable about this type of therapeutic approach is that the first people who are going to see the impact are not actually the physicians – it’s the families,
Regeneron gene therapy helps deaf children hear in small study
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s treatment, new data show.
Evidence builds behind Regeneron's deafness gene therapy
Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by Regeneron have seen notable improvements in hearing, according to new data from the CHORD trial.
Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a mutation to the otoferlin gene. The company snapped up DB-OTO through its $109 million acquisition of Decibel Therapeutics in 2023.
Regeneron’s Gene Therapy Restores Hearing in Patients with Rare Genetic Deafness
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic deafness.
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one-time treatment.
Regeneron reports positive results for deafness therapy
Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment of profound genetic hearing loss in children due to certain variants of the OTOF gene.
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's sixth consecutive day of gains.
Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts
We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...
5REGN : Regeneron Pharmaceuticals Unusual Options Activity...
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...
US must meet tougher standard in Regeneron kickback lawsuit
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
JD Supra5h
First Circuit Adopts “But For” Causation Standard under the Anti-Kickback Statute, Paving the Way for Potential Supreme Court Review
Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals with ...
Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...
Regeneron announces updated DB-OTO data from CHORD trial
Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have ...
JD Supra1d
Narrowing FCA Cases Based on Kickback Allegations: What Healthcare and Life Sciences Companies Need to Know About the Regeneron Decision
On February 18, 2025, in a closely watched decision, the United States Court of Appeals for the First Circuit in United States v.